Mental or Behavioral Dysfunction – Page 6

BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis

7 months ago talkbio0Tagged Alzheimer's Disease, Approved, KarXT, Mechanism (attribute), Muscarinic Agonists, Myers, Psychotic Disorders, Schizophrenia, squibb, United States Food and Drug Administration

KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.

Psyence Biomed to Acquire Clairvoyant Therapeutics, Expanding Psilocybin-Based Therapeutic Pipeline

8 months ago talkbio0Tagged Acquisition (action), Alcohol Use Disorder, biomed, Clairvoyant, Clinical Trials, Hallucinogens, Psilocybin, Psyence

Psilocybin, Psyence Biomed, Clairvoyant Therapeutics, Acquisition, Alcohol Use Disorder (AUD), Clinical Trials, Psychedelic Therapeutics

Astellas Closes California Facility; Takeda Expands ADHD Drug Production Amid Generic Competition

8 months ago talkbio0Tagged Astellas, Attention deficit hyperactivity disorder, competition, Facility (object), Reparative closure, Takeda, Vyvanse

Astellas, Takeda, ADHD drug, Vyvanse, generic competition, facility closure

Neurocrine Biosciences Advances Schizophrenia Treatment with Positive Phase 2 Data for NBI-1117568

8 months ago talkbio0Tagged Biosciences, Muscarinic Agents, NBI-1117568, Neurocrine, Phase 2, Phase 3, Schizophrenia

Neurocrine Biosciences, schizophrenia, NBI-1117568, Phase 2 data, Phase 3 advancement, muscarinic M4 selective acetylcholine receptor agonist

Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial

8 months ago talkbio0Tagged AbbVie, Antipsychotic Agents, Biosciences, Emraclidine, KarXT, Muscarinic Acetylcholine Receptor, Myers, NBI-1117568, Neurocrine, Schizophrenia, squibb

Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics

Semaglutide and Mental Health: A Complex Relationship

8 months ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, ideation, mental health, semaglutide, Suicidal

semaglutide, mental health, suicidal ideation, GLP-1 drugs, weight loss, diabetes

Astellas Employee Indicted by China’s Prosecutors on Espionage Charges

8 months ago talkbio0Tagged Astellas Pharma, China, Diplomatic, espionage, indictment, Japan, Tension

Astellas Pharma, China, Japan, espionage, indictment, diplomatic tensions

FDA’s Rejection of Lykos’ MDMA-Assisted Therapy for PTSD: A Setback but Not a Roadblock for Psychedelic Research

8 months ago talkbio0Tagged Clinical Trials, ethical violations, Intact, Midomafetamine, Post-Traumatic Stress Disorder, psychedelic therapy, Rejection (Psychology), Science, United States Food and Drug Administration

MDMA, PTSD, Lykos Therapeutics, FDA rejection, psychedelic therapy, clinical trials, ethical violations, scientific integrity.

Lykos Faces Significant Setbacks as FDA Rejects MDMA Therapy and Three Studies Are Retracted Due to Unethical Conduct

8 months ago talkbio0Tagged Clinical Research, Lykos ', Midomafetamine, Post-Traumatic Stress Disorder, psychedelic research, Rejection (Psychology), unethical conduct, United States Food and Drug Administration

Lykos Therapeutics, MDMA therapy, FDA rejection, study retractions, unethical conduct, PTSD treatment, psychedelic research

Eisai’s Alzheimer’s Drug Leqembi Shows Long-Term Benefits, Despite Study Limitations

9 months ago talkbio0Tagged Alzheimer 's drug, Amyloid, Benefit, Biogen, Clinical Research, Eisai, Leqembi, Long-term, Mental deterioration, Plaque (lesion)

Eisai, Leqembi, Alzheimer’s drug, long-term benefits, study limitations, cognitive decline, amyloid plaques, Biogen